Linscomb Wealth Inc. Purchases Shares of 517 Intuitive Surgical, Inc. (NASDAQ:ISRG)

Linscomb Wealth Inc. purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 517 shares of the medical equipment provider’s stock, valued at approximately $270,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Berbice Capital Management LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department bought a new stake in Intuitive Surgical in the 4th quarter worth approximately $28,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth approximately $33,000. Decker Retirement Planning Inc. bought a new position in shares of Intuitive Surgical during the 4th quarter valued at approximately $36,000. Finally, Sierra Ocean LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter valued at $40,000. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 408 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total value of $240,618.00. Following the transaction, the executive vice president now directly owns 353 shares in the company, valued at $208,181.75. The trade was a 53.61 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,077 shares of company stock worth $4,620,025. Company insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Truist Financial upped their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. Jefferies Financial Group lifted their price target on Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Leerink Partners boosted their price objective on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. raised their price objective on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $573.15 on Friday. The stock has a market cap of $204.14 billion, a price-to-earnings ratio of 89.42, a price-to-earnings-growth ratio of 5.85 and a beta of 1.39. The firm has a 50-day moving average of $569.87 and a two-hundred day moving average of $528.64. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.